Trim 10/11/2023
Neuren Pharmaceuticals (NEU)
*** GENERAL ADVICE ONLY ***
Description
Industry: Bio-Pharma
Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders
Metrics
Market Cap: $1.7B
PE: 31
Yield: N/A
Trade
Allocation: 3% Entry: $12.13 (10th Aug) & $11.35 (14th Sept)
Recommendation to Trim: 1% >$14.25 (+22%)
Catalyst
Technical – Approaching all time highs for NEU, we feel a trim of a further 1% of the position is prudent, leaving a 2% allocation in the Balanced Portfolio
On the 3rd of November NEU reported highlights from the Q3 2023 earnings announcement and conference call of its partner Acadia Pharmaceuticals. Acadia announced Q3 net sales of DAYBUE ™ (trofinetide) in the United States of US$66.9 million, well above market expectations
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.